Patents by Inventor Marianna Zaretzky

Marianna Zaretzky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-17R-ECD mutants and methods of using same
    Patent number: 9850294
    Abstract: A protein comprising an amino acid sequence having at least 97% homology to SEQ ID NO: 1. The amino acid sequence comprises valine at position 60, glycine at position 123 and lysine at position 109 and the protein binds hIL17A.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: December 26, 2017
    Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV, LTD.
    Inventors: Amir Aharoni, Marianna Zaretzky
  • NOVEL IL-17R-ECD MUTANTS
    Publication number: 20160376343
    Abstract: A protein comprising an amino acid sequence having at least 97% homology to SEQ ID NO: 1. The amino acid sequence comprises valine at position 60, glycine at position 123 and lysine at position 109 and the protein binds hIL17A.
    Type: Application
    Filed: July 8, 2016
    Publication date: December 29, 2016
    Inventors: AMIR AHARONI, MARIANNA ZARETZKY
  • IL-17R-ECD mutants and methods of using same
    Patent number: 9416168
    Abstract: Provided are engineered soluble hIL-17RA receptors with high affinity to hIL-17 that inhibit downstream IL17A induced signaling events in cells. Also provided are methods of inhibiting hIL-17A induced secretion of CXCL1 and/or IL-6 in cells, as well as methods of treating inflammation and/or inflammatory disorders in a subject.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: August 16, 2016
    Assignee: The National Institute for Biotechnology in the Negev, Ltd
    Inventors: Amir Aharoni, Marianna Zaretzky
  • NOVEL IL-17R-ECD MUTANTS
    Publication number: 20150025022
    Abstract: Provided are engineered soluble hIL-17RA receptors with high affinity to hIL-17 that inhibit downstream IL17A induced signaling events in cells. Also provided are methods of inhibiting hIL-17A induced secretion of CXCL1 and/or IL-6 in cells, as well as methods of treating inflammation and/or inflammatory disorders in a subject.
    Type: Application
    Filed: July 18, 2012
    Publication date: January 22, 2015
    Inventors: Amir Aharoni, Marianna Zaretzky